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X-RAY DIFFRACTION POWDER DATA FOR STEROIDS: SUPPLEMENT III 
including a 
DISCUSSION OF STEROID NOMENCLATURE 
JONATHAN PARSONS*, S. T . WONG*, W I L L I A M T . BEHER**, AND GIZELLA D . BAKER** 
T H E X-RAY DIFFRACTION powder data for steroids given in this paper comprise an 
extention to the sets of data previously published in past issues of the Henry Ford 
Hospital Medical Bulletin.''^^ Because there exists a lack of agreement with respect 
to steroid nomenclature, a section is included with this report explaining some of the 
ways in which the different steroids are classified and showing methods used for 
naming the majority of these compounds. 
DESCRIPTION OF TABLES 
The procedures used for obtaining the present data were the same as previously 
reported.'^^ Table I I is a classified list of steroids studied in this group. Their 
molecular formulas and corrected melting point ranges are given. Table I I I gives for 
each steroid the consecutively numbered data groups consisting of the interplanar 
spacings (d) in angstrom units and the relative intensities ( I / I i ) with Ii being the 
intensity of the strongest line of the group. 
PURITY OF STEROIDS 
In work with each steroid the foOowing steps are taken in order to ascertain 
the purity of the compound. (1) An x-ray diffraction powder pattern is obtained 
for each steroid as received from its commercial source. (2) The steroid is then 
recrystallized from ethanol, if possible, or from an alternative solvent as indicated 
in Table I I . (3) A new powder pattern and melting point determination are then 
made for the recrystallized steroid. The melting point range thus determined is 
checked with that reported in the chemical literature. Any steroid whose melting 
point differs significantly from the literature reported values is held up for further 
investigation as to its purity. 
*Edsel B. Ford Institute for Medical Research, Department of Physics. 
**Edsel B. Ford Institute for Medical Research, Department of Biochemistry. 
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POLYMORPHIC FORMS 
When the x-ray diffraction powder patterns before and after recrystallization 
are identical, and their melting point ranges agree with the literature, only one 
crystalline form is present and the data is included as representing the ethanol (or 
other solvent) recrystallized form. Where different patterns are obtained before and 
after recrystallization two polymorphic forms are present and the data is included 
for the unrecrystallized form as well as for the ethanol (or other solvent) recrystallized 
states. In cases where the melting point ranges differ slightly before and after 
recrystaflization, this information is listed in Table I I . It should be emphasized that 
more than two forms for the same steroid often exist and the inclusion of data for 
only one or two of these polymorphic forms does not mean that other crystalline 
forms with different x-ray diffraction powder patterns are not possible. 
STEROID NOMENCLATURE 
Steroid nomenclature is at present in a confused state. An international com-
mission has agreed and formulated a standard nomenclature; however its universal 
acceptance has not been achieved. Nomenclature in this field has been further 
confused inasmuch as many steroids have useful pharmacological properties and 
each drug house manufacturing or marketing a given steroid has conferred its own 
trivial name to these products. As an example of the multiplicity of names given a 
single compound, the Merck Index lists 14 names for A''-Androsten-17(,8)-oI-3-one 
(testosterone). While no attempt will be made to cover all methods of naming a 
given steroid it is hoped that sufficient background will be provided so that the 
reader can decipher the structure of a steroid regardless of the system of nomenclature 
used. This, of course, does not apply to the use of trivial names, a practice which 
should be abandoned. The only recourse in these cases is to find the alternate 
chemical nomenclature in drug bulletins, Merck Index, etc. 
All of the true steroids are characterized by the presence of the cyclopentano-
perhydrophenanthrene nucleus. Figure 1. In the shorthand of the chemist the hydrogens 
are omitted from the ring structure as in Figure la which is fully equivalent to 
Figure 1 and the hydrogen atoms are understood to be present at each of the carbons 
which in turn are represented by the junctures of two lines. In certain special cases, 
e.g. stereo considerations it is necessary to include certain hydrogens in writing the 
.structure. This fully saturated alicyclic nucleus is altered by substitution and dehydro-
oenation in various steroids. 
Figure I Figure la 
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In order to designate the position of substitution or dehydrogenation the carbon 
atoms of the nucleus have been assigned numbers which are universally accepted. 
The numbering and lettering of the cyclopentanoperhydrophenanthrene nucleus is 
shown in Figure 2. 
Figure 2 
With the exception of the estrogens and a few other compounds all of the steroids 
have methyl groups substituted for hydrogens at position 10 and 13. Since most 
steroids contain these methyl groups they are assumed to be present and their presence 
is not designated as a nuclear substitution. The methyl group at position 10 is 
missing in the estrane series of compounds. Since the methyl groups are not designated 
by substitution they have been assigned numbers 18 and 19, Figure 3 a. These methyl 
groups are commonly represented in formulae by heavy strokes. Figure 3b. 
Figure 3 a Figure 3 b 
One of the hydrogen atoms at position 17 may be substituted by a chain of 
carbons of varying length. Since the order and arrangement but not the number of 
the carbon atoms in the 17 side chain are the same in afl of the steroids substituted 
at this position, standard numbering of the side chain carbons has been devised. 
This numbering system is illustrated using the side chain of the cholestane series 
as an example, Figure 4. 
The steroid nucleus has been shown by x-ray diffraction to be planar. The 
bond angles of carbon atoms in the nucleus are such, that the hydrogen atoms on 
each of the carbon atoms lie either above or below the plane of the nucleus, (one 
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above and one below). The methyl groups (angular methyls) 18 and 19 have been 
shown to be oriented on the same side of the nuclear plane in all known steroids. 
The configuration (above or below the nuclear plane) of all other substituting groups 
are cis or trans (same or opposite side respectively) with respect to the angular 
methyl groups. Those atoms or radicals cis with respect to the angular methyls are 
designated to have the /8 configuration and are always joined to the nucleus by a 
solid line. Those trans with respect to the angular methyls are designated a and are 
joined to the nucleus with a dotted line, Figures 5 and 6. I f the configuration is 









Since some of the carbon atoms in the nucleus contain only one hydrogen atom 
(position 5, 8, 9, 14), it is necessary to designate the configuration of these hydrogen 
atoms (a or /S) inasmuch as the properties, identity, and nuclear configuration of 
the steroids depend upon these parameters. Fortunately the configuration of afl of 
these hydrogens with the exception of the one at position five seldom change and 
2'^  
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for purposes of nomenclature we can disregard them. The importance of the con-
figuration at position five will become apparent later, it may be either a or /3, Figure 
8 and 9. 
H 
5/3 
Figure 8 Figure 9 
Most of the steroids commonly encountered may be classified as substitution 
products of 9 major hydrocarbons which differ only in the configuration of the 
hydrogen atom at position five and the side chain substitution at carbon 17. The 
hydrocarbons, their structure and alternate names are shown in structural formulas 













































These hydrocarbons may be referred to as stem compounds. One other series of 
compounds are generally treated as stem compounds, they are cholanic acid, nor-






Cholanic Acid Norcholanic Acid 
Figure 19 Figure 20 
' H - C O O H 
COOH 
Bisnorcholanic Acid Etiocholanic Acid 
Figure 21 Figure 22 
These stem compounds make it possible to name systematicafly most of the 
steroids encountered. They are not sufficient to systematically name the sapogenins 
and other steroids with complex side chains, however, these compounds are seldom 
named systematically and we wfll limit ourselves to trivial names in these cases. 
Steroids differ from one another due to the different stems discussed above and 
substitution for hydrogen atoms on the steroid nucleus by various atoms and radicals. 
The most common of these are shown in Table I . Since in many of the positions 
there are two hydrogen atoms of different configuration (one a and one ,8) the atom 
or radical replacing a given hydrogen may be either of the a or ,S configuration and 
this configuration must be specified inasmuch as the properties of the molecule 
depend upon this parameter. The position configuration of the substitution or sub-
stitutions are designated by placing the number of the position first and the a or j8 
configuration and the nomenclature designation last. 
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Table I 
SUBSTITUTION SYMBOL or FORMULA NOMENCLATURE 
Cyanide -C=N Cyano or Carbonitrile 
Hydroxy -OH -ol 
Ketone () -one (or Keto in cholanic 
acid series) or 0x0 
Nitro -NO2 -nitro 
Methyl -CH3 -methyl 
Ethyl -CH2CH3 -ethyl 
Ethynyl -C~CH -ethynyl 
Epoxy or oxido -0- -epoxy or oxido 
Chlorine 
-c -chloro 
Bromine Hi -bromo 
Iodine -1 -iodo 
Fluorine 1 -fluoro 
1) Deoxy signifies that there is no oxygen at a certain position, this prefix is used with trivial 
names only. 
2) Nor denotes the loss of one carbon from a chain, bisnor two carbons. 
Thus we have 3(y8)-ol, 3(a)-ol, 3-one, etc. Any number of substitutions may 
take place in a given steroid. Multiple substitutions by a single atom or radical are 
indicated by series designation of the positions of substitution and their configuration 
followed by the prefixes di, tri, tetr, etc., and then the nomenclature designation. 




Figure 24 would be 5/8-androstan-3,7,12-trione. Of course, we could classify 
the steroid. Figure 23, as a trihydroxymonoketone and Figure 24 as a triketone. 
Since cis-trans isomerism is not involved in ketone substitution no a or /8 designation 
is made or is possible. 
An important exception to the order of placement of the substitution products 
and their designations is seen in the series of compounds derived from the stems 
3(1 
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cholanic, nor-cholanic, bisnorcholanic and etiocholanic acids. In naming such steroids 
the position number of the substituting atoms or radicals and their full names precede 
the stem name, thus. Figure 25 is 3(fl),7(o),12(a)-trihydroxycholanic acid. Figure 









The prefix epi is encountered at times. This designation is used to indicate that 
the configuration of the hydroxyl in the compound is oriented in the opposite manner 
with respect to the orientation in the natural or typical steroid. 
Steroids differ by the amount of unsaturation of the molecule. I f two hydrogen 
atoms are removed between adjacent carbon atoms a double bond is introduced and 
the molecule is said to be unsaturated due to the fact that various reagents may add 
across the double bond without replacing hydrogen atoms. For designating the 
position of unsaturation we run into some confusion inasmuch as several systems 
have been used. In one system the Greek A followed by a smafl superscript is used. 
Thus, the steroid in Figure 28 would be A ' - It is obvious that saying A ' does not 
indicate whether the double bond is between 5 and 6 or 5 and 4, however, the system 
dilates that the double bond is between the superscript and the next highest position. 
However, what would one do if a double bond was to be designated between 8 and 
14? Here the second number would be placed as a superscript in parenthesis. Thus, 
the steroid in Figure 29 is A*'"'- The stem name is amended by substitution of an 
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e in place of the final a in the stem. Thus, the steroid in Figure 30 would be 
cholestan-3(/3)-ol and Figure 31 A'-cholesten-3(/3)-ol. If more than one double 
bond is involved the final n in the stem is replaced by dien, trien, etc., and another 
superscript is added after the A following a comma. Thus, the steroid in Figure 32 
is A''-cholestadien-3(/3)-ol. 














Some authors add a final e at the end of the stem designation thus cholesten= 
cholestene, dien=diene, trien==triene, etc. Some authors omit the A and place the 
number followed by a dash in front of the tem, thus, the steroid shown in Figure 
33 can be named, A4-androsten-3,17-dione or 4-androsten-3,17-dione. 
Figure 33 
In another method the prefix dehydro is used to signify unsaturation. This prefix 
is usually preceded by a number indicating the position of unsaturation and is 
followed by the trivial or common name of the steroid. The steroid in Figure 34, 
would be called 7-dehydrocholesterol. The use of this prefix is confusing inasmuch 
as it is also used to indicate the elimination of two hydrogens from a hydroxyl with 
formation of a ketone (oxidation). An example is shown in Figure 35, where we 








Figure 35 Figure 36 
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Still another system of designating unsaturation is illustrated by the steroid in 
Figure 36. We would call this steroid androst-5-en-3(/3)-ol-17-one. In this system 
the stem minus the suffix -ane is followed by the position number of the unsaturation 
and this in turn is followed by -en. In the case of multiple unsaturation more than 
one position number is used followed by diene, triene, etc. Steroids derivaties such as 
esters, ethers, and acetals are named by writing the structural designation of the parent 
compound first and following this by the position number or numbers of the derivative 
and then the name of the derivative or derivatives. The derivatives shown in Figure 












In an alternate type of nomenclature. Figure 37 is called 3(y8)-acetoxy-A'-
cholesten. The methyl esters of cholanic, norcholanic, bisnorcholanic, and etiocholanic 
acid are named by placing the word methyl first followed by the stem name with the 
ending -ic replaced by ate. Ethyl and higher esters would be named similariy. An 
example would be methyl cholanate. 
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Table I I 
































































/\<-Pregnen-3, 11, 20-trione 
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^4_pregnen-l la-ol-3, 20-dione'' 
( I la -Hydroxy progesterone) 
A^-Pregnen-1 la-ol-3, 20-dione 
( I la-Hydroxy progesterone) 
/»j^-Pregnen-17a-ol-3, 20-dione-17-acetate 
(17a-Hydroxy progesterone acetate) 
Dihydroxy-triketones 
5a-Pregnan-17a, 21-diol-3, 11, 20-trione-21-acetate" 
5a-Pregnan-17a, 21-diol-3, 11, 20-trione-21-acetate 
Trihydroxy-diketones 
5^-Pregnan-3a, 17a, 21- t r io l - l l , 20-dione-21-acetate 
Carboaikoxy acids 
3a, 7^-Dihydroxycholanic acid 
(Ursodeoxycholic acid) 
3a, 12a-Dihydroxy-/\'-(''')-cholemc acid 
(Apocholic acid) 
3a, 6o, 7a-Trihydroxycholanic acid 
(Hyocholic acid) 
Sapogenins and sapogenin derivatives 
Kryptogenin 
Digitalis glycosides 




(Diethylstilbestrol dimethyl ether) 
3, 4-Bis (p-dipalmitoxyphenyl)-3-hexene 
(Diethylstilbestrol dipalmitate) 
"Recrystallized f rom acetone 




C j , H31, O3 
C23 H32 O4 
C23 H32 O j 
^23 1^ 32 ^ 6 
C23 O j 
C24 H41, O4 
C24 H35 O4 
C24 H4(, O5 

















PARSONS, WONG, BEHER 
Table I I I 
1 2 
d,A l / I , d,A I / I , 
12.36 0.41 15.16 0.06 
9.83 0.08 10.49 0.30 
8.39 0.02 7.95 0.04 
7.50 0.11 6.85 0.08 
7.03 0.08 6.18 0.15 
6.63 O. l l 5.80 0.03 
6.03 0.05 5.49 1.00 
5.59 1.00 5.22 0.01 
5.39 0.15 4.68 0.20 
5.17 0.20 4.33 0.08 
4.77 0.08 3.99 0.11 
4.31 0.11 3.82 0.01 
4.14 0.03 3.69 0.02 
4.01 0.27 3.54 0.06 
3.79 0.08 3.40 0.01 
371 0.02 3.25 0.01 
3.51 0.08 3.18 0.01 
3.27 0.04 3.09 0.01 
3.20 0.02 2.96 0.02 
3.12 0.01 2.77 0.03 
2.98 0.02 2.52 0.02 
2.92 0.01 2.47 0.02 
2.84 O.OI 2.38 0.01 
2.75 0.01 2.34 0.01 
2.68 0.01 2.28 0.04 
2.60 0.07 2.18 0.02 




2.19 0.07 5 
2.13 0.07 d,A I / I i 
2.07 0.02 14.03 0.13 
2.00 0.07 12.11 0.02 







4 5.04 0.49 
I / I i 4.80 0.27 
10.69 0.50 4.68 0.36 
8.96 0.20 4.43 0.04 
7.82 0.15 4.24 0.11 
7.07 0.10 4.06 0.13 
5.71 0.20 3.89 0.09 
5.55 0.27 3.79 0.04 
5.33 0.07 3.65 0.07 
5.06 0.05 3.51 0.07 
4.92 1.00 3.30 0.04 
4.64 0.07 3.20 0.01 
4.48 0.07 3.12 0.01 
4.25 O.OI 3.02 0.13 
3.91 0.24 2.93 0.09 
3.62 0.02 2.82 0.02 
3.47 0.15 2.59 0.03 
3.08 0.07 2.54 0.01 
2.64 0.01 2.47 0.02 
2.56 0.01 2.38 0.02 
2.48 0.01 2.30 O.OI 
2.24 0.02 2.23 0.02 
2.18 0.01 2.15 0.02 
2.11 0.02 2.11 0.03 
2.05 O.OI 2.01 0.04 







































d,A I / I i d,A I / I , d,A I / I , 
13.15 0.15 12.19 0.27 16.58 0.15 
11.38 0.15 10.65 0.02 6.08 0.40 
9.64 0.20 8.01 0.17 5.58 1.00 
8.03 0.01 7.00 0.09 5.22 0.04 
7.46 0.50 6.61 0.13 5.02 0.05 
6.38 0.07 6.07 1.00 4.76 0.08 
6.02 0.80 5.85 0.01 4.58 0.63 
5.71 0.88 5.59 0.67 4.35 0.04 
5.43 0.44 5.28 0.17 4.14 0.03 
5.23 I.OO 4.85 0.36 4.03 0.04 
4.96 0.15 4.63 0.20 3.87 0.04 
4.79 0.15 4.26 0.09 3.76 0.08 
4.54 0.20 3.98 0.17 3.66 0.06 
4.35 0.27 3.84 0.02 3.53 0.04 
4.18 0.20 3.61 0.02 3.39 0.04 
4.02 0.20 3.43 0.03 3.06 0.11 
3.86 0.01 3.33 0.02 3.00 0.01 
3.72 0.27 3.12 0.01 2.91 0.06 
3.59 0.15 3.04 0.01 2.84 0.01 
3.35 0.07 2.87 O.OI 2.75 0.06 
3.29 0.10 2.80 0.02 2.55 0.01 
3.21 0.10 2.68 0.02 2.49 0.03 
3.11 0.02 2.57 0.01 2.29 0.06 
3.04 0.02 2.48 O.OI 2.17 0.01 
3.00 0.15 2.43 O.OI 2.09 0.01 
2.82 0.13 2.22 0.02 2.04 0.02 
2.73 0.03 1.96 0.02 




2.23 0.15 11 













d,A I / I i 9.23 0.05 
9 11.90 0.11 8.56 0.04 
d,A I / I , 8.91 0.05 8.09 0.05 
14.30 0.15 8.06 0.05 6.72 0.04 
11.22 0.10 7.67 0.02 6.40 0.05 
7.15 0.03 6.90 0.05 6.14 0.04 
677 0.10 6.54 0.08 5.74 1.00 
6.22 0.08 6.22 0.08 5.35 0.08 
6.03 0.27 6.01 0.28 4.78 0.73 
5.84 0.10 5.69 1.00 4.57 0.05 
5.51 1.00 5.48 0.15 4.27 0.15 
5.18 0.50 5.24 0.20 4.09 0.08 
4.88 0.18 5.00 0.56 3.78 0.08 
4.58 0.07 4.33 0.11 3.66 0.01 
4.36 0.03 4.17 0.08 3.54 0.05 
4.19 0.07 3.85 0.08 3.22 0.11 
4.08 0.15 3.71 0.03 3.11 0.04 
3.92 0.10 3.57 0.03 3.03 0.01 
3.72 0.20 3.35 0.08 2.89 0.02 
3.56 0.01 3.25 0.01 2.76 0.02 
3.34 O.OI 3.13 0.02 2.66 0.01 
3.25 0.05 3.00 0.08 2.58 0.01 
3.15 0.01 2.83 0.05 2.52 0.04 
2.96 0.01 2.65 O.OI 2.44 0.01 
2.83 0.07 2.58 O.OI 2.38 0.01 
2.76 0.01 2.45 0.02 2.29 0.10 
2.57 0.01 2.40 0.02 2.19 0.01 
2.38 0.01 2.35 0.03 2.14 0.01 
2.24 0.02 2.20 0.03 2.07 0.01 
2.20 0.05 2.16 0.01 2.01 O.OI 
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12 13 
d,A I / I , d,A I / I , 
12.28 0.11 11.77 0.07 
8.98 0.08 9.98 0.05 
6.15 0.40 8.84 0.05 
5.45 1.00 8.15 0.02 
5.10 0.08 7.49 0.11 
4.72 0.06 6.60 0.01 
4.46 0.03 6.02 1.00 
4.34 0.30 5.59 0.02 
4.00 0.07 5.39 0.02 
3.88 0.03 5.01 0.41 
3.79 0.01 4.20 0.10 
3.40 0.08 4.02 0.04 
3.31 O.OI 3.86 0.04 
3.18 O.U 3.68 0.04 
3.07 0.13 3.51 0.04 
2.98 0.03 3.38 0.05 
2.87 0.05 3.09 0.04 
2.81 0.04 3.02 0.01 
2.75 0.06 2.94 0.01 
2.64 O.OI 2.88 O.OI 
2.55 0.04 2.75 0.02 
2.50 0.05 2.62 0.02 
2.42 0.03 2.54 0.03 
2.30 0.06 2.40 O.OI 
2.18 0.06 2.25 0.01 
2.14 0.05 2.20 0.04 
2.08 0.05 2.08 O.OI 
2.03 0.04 2.01 0.01 
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20 21 22 
d,A I / I , d,A I / I , d,A I / I , 
10.34 0.27 11.15 0.15 11.48 0.08 
6.86 0.10 8.44 0.20 8.34 0.03 
6.30 0.20 6.45 0.32 6.86 0.01 
6.13 1.00 6.01 I.OO 6.26 0.40 
5.89 0.10 5.44 0.75 5.99 0.04 
5.66 0.07 5.15 O.IO 5.74 0.06 
5.40 0.75 5.00 0.23 5.57 I.OO 
5.05 0.63 4.80 0.20 5.10 0.30 
4.77 0.27 4.49 0.27 4.82 0.04 
4.47 0.15 4.19 0.23 4.56 0.03 
4.17 0.37 3.99 0.07 4.37 0.06 
3.90 0.01 3.84 0.10 4.17 0.08 
3.70 0.03 3.70 0.05 4.02 0.05 
3.65 0.15 3.50 0.15 3.90 O.OI 
3.53 0.03 3.34 0.01 3.79 0.02 
3.44 0.15 3.18 0.15 3.67 0.06 
3.31 0.15 3.09 0.13 3.54 O.OI 
3.20 0.02 3.01 0.20 3.43 0.04 
3.14 0.01 2.94 0.09 3.33 0.05 
3.06 0.07 2.86 0.07 3.24 0.02 
2.96 0.03 2.78 0.13 3.16 0.25 
2.74 0.10 2.66 0.09 3.07 0.08 
2.66 0.07 2.62 0.07 2.98 0.04 
2.60 0.05 2.56 0.03 2.88 0.02 
2.55 O.IO 2.51 0.09 2.83 0.08 
2.40 0.03 2.42 O.OI 2.78 0.02 
2.31 0.02 2.36 0.03 2.72 0.02 
2.25 0.02 2.32 0.02 2.67 0.01 
2.19 0.13 2.27 0.05 2.56 0.04 
2.11 O.OI 2.08 0.03 2.51 0.03 
2.03 0.02 2.05 0.02 2.40 0.09 
1.93 0.01 1.99 0.02 2.34 0.02 
1.87 O.OI 1.90 0.03 2.30 0.01 




23 24 25 
d,A I / I , d,A I / I , 
11.36 0.11 11.05 0.15 
7.88 0.15 9.56 0.10 
6.93 0.01 7.20 0.07 
6.16 1.00 6.30 0.88 
5.76 0.27 5.81 0.50 
5.51 0.02 5.50 1.00 
5.33 0.87 5.23 0.20 
5.04 0.20 4.77 0.18 
4.49 0.15 4.58 O.OI 
4.15 0.20 4.40 0.37 
3.93 0.08 4.25 0.07 
3.76 0.08 4.21 0.27 
3.63 0.03 4.12 0.15 
3.47 0.13 3.98 0.20 
3.32 0.08 3.67 0.07 
3.22 0.11 3.48 0.13 
3.09 0.02 3.37 0.02 
2.98 0.03 3.29 0.03 
2.86 0.08 3.16 0.15 
2.70 0.02 3.06 0.01 
2.62 0.04 2.91 0.03 
2.58 0.03 2.75 0.07 
2.53 0.04 2.59 0.03 
2.47 0.02 2.49 0.02 
2.42 0.01 2.45 0.03 
2.37 0.08 2.35 0.10 
2.32 0.08 2.24 0.05 
2.22 0.07 2.19 0.02 
2.13 0.03 2.15 0.01 
2.01 0.02 2.12 0.02 
1.99 0.01 2.07 0.03 
1.95 0.01 1.96 0.02 
1.91 0.03 1.93 0.02 
1.88 0.04 1.90 0.01 
1.82 0.03 1.83 0.03 
1.79 0.04 
26 


































































































PARSONS, WONG, BEHER AND BAKER 
29 30 31 
d,A I / I , d,A I / I , d,A I / I , 
10.78 0.11 1171 0.11 12.24 0.11 
7.76 0.05 10.92 0.08 6.72 0.01 
7.37 0.08 6.19 0.38 6.00 1.00 
6.42 0.11 5.93 0.24 5.75 0.20 
6.12 1.00 5.50 1.00 5.15 0.41 
5.77 0.01 5.23 0.11 4.94 0.05 
5.50 0.56 5.01 0.15 4.58 0.34 
5.31 0.38 4.81 0.01 4.05 0.05 
4.90 0.07 4.61 0.05 3.81 0.02 
4.77 0.08 4.45 0.20 3.70 0.02 
4.52 0.01 4.29 0.28 3.59 0.08 
4.37 0.11 4.14 0.03 3.33 0.01 
4.17 0.05 3.92 0.01 3.15 0.04 
4.00 0.03 3.82 0.11 3.04 0.15 
3.83 0.33 3.55 0.08 2.85 0.08 
3.68 0.02 3.37 0.13 2.76 0.03 
3.47 0.08 3.30 0.10 2.69 0.02 
3.28 0.10 3.10 0.08 2.57 0.05 
3.13 0.01 2.97 0.01 2.47 0.08 
3.06 0.03 2.90 0.03 2.38 0.01 
2.91 O.OI 2.80 O.OI 2.33 0.01 
2.80 0.10 2.75 0.01 2.29 0.02 
2.64 0.08 2.71 0.04 2.26 0.01 
2.56 0.02 2.66 0.04 2.15 0.01 
2.45 O.OI 2.61 0.04 2.08 0.08 
2.37 0.01 2.54 0.03 2.05 0.03 
2.31 0.05 2.41 0.05 1.99 0.03 
2.25 0.03 2.31 0.05 1.95 0.04 
2.19 0.15 2.24 0.03 1.89 0.01 
2.08 O.OI 2.20 0.01 1.84 0.02 
2.04 0.01 2.15 0.03 
1.99 0.01 2.07 0.05 
1.96 0.01 2.00 0.04 
1.88 0.01 1.96 0.01 
1.82 0.04 1.90 0.03 
44 
POWDER DATA 
32 33 34 
d,A I / I , d,A I / I , d,A I / I , 
8.27 0.15 13.56 0.08 7.37 0.28 
6.89 0.37 6.93 0.04 7.03 0.02 
6.51 1.00 6.08 0.27 6.51 0.20 
5.61 0.88 5.91 0.15 6.24 1.00 
5.36 0.03 5.53 1.00 5.72 0.20 
5.14 0.88 5.11 0.27 5.54 0.38 
4.62 0.32 4.88 0.41 5.32 0.02 
4.50 0.15 4.73 O.OI 4.73 0.33 
4.21 0.20 4.55 0.55 4.55 0.20 
3.93 0.07 4.05 0.03 4.37 0.03 
3.85 0.03 3.70 0.11 4.19 0.47 
3.75 0.03 3.58 0.08 4.01 0.05 
3.51 0.10 3.44 0.11 3.88 0.05 
3.43 0.03 3.29 0.10 3.76 0.05 
3.34 0.09 3.14 0.11 3.66 0.11 
3.27 0.09 3.08 0.03 3.37 0.20 
3.16 0.15 2.97 0.27 3.25 0.11 
3.06 0.05 2.88 0.11 3.15 0.15 
3.00 0.05 2.76 0.08 2.96 0.08 
2.90 0.02 2.69 0.05 2.75 0.05 
2.81 0.15 2.65 0.02 2.71 0.08 
2.70 0.07 2.59 0.01 2.64 0.05 
2.63 0.02 2.51 0.11 2.56 0.11 
2.57 0.05 2.41 0.01 2.47 0.02 
2.49 0.03 2.37 0.05 2.39 O.OI 
2.42 0.01 2.31 0.04 2.28 0.03 
2.38 0.02 2.26 0.05 2.21 0.03 
2.32 0.05 2.20 0.08 2.17 0.03 
2.25 0.03 2.14 0.11 2.12 0.05 
2.18 0.03 2.08 0.01 2.06 0.03 
2.11 0.10 2.04 0.05 2.00 0.02 
2.07 0.01 2.00 0.07 1.94 O.OI 
2.03 0.03 1.96 0.08 1.92 O.OI 
2.00 0.02 1.92 0.05 1.85 0.03 
1.92 0.07 
45 
PARSONS, WONG. BEHER AND BAKER 
35 36 37 
d,A I / I , d,A I / I , d,A I / I , 
11.33 0.13 9.61 0.28 14.98 0.15 
8.76 0.55 7.94 0.11 13.28 0.02 
7.08 0.27 7.14 0.08 8.80 0.08 
6.28 0.15 6.58 0.24 7.58 0.08 
5.85 0.02 6.37 0.47 6.44 0.01 
5.64 0.73 6.05 0.01 5.89 I.OO 
4.94 0.08 5.64 I.OO 5.59 0.75 
4.72 0.11 5.44 0.56 5.02 0.20 
4.50 1.00 5.19 0.08 4.74 0.11 
4.39 0.05 4.96 O.I I 4.51 0.08 
4.08 0.18 4.74 0.15 4.34 0.38 
3.82 0.05 4.37 0.11 4.16 0.10 
3.67 0.03 4.19 0.20 3.99 0.08 
3.57 0.03 4.04 O.IO 3.87 0.08 
3.38 0.03 3.89 0.08 3.72 0.02 
3.30 0.05 3.76 0.03 3.59 0.03 
3.21 0.02 3.66 O.IO 3.45 0.08 
3.07 O.OI 3.59 O.OI 3.37 0.03 
2.97 0.05 3.39 0.20 3.27 0.04 
2.91 0.08 3.30 0.01 3.18 0.04 
2.77 0.05 3.18 0.15 3.07 0.04 
2.60 0.11 3.04 0.05 2.99 0.02 
2.52 0.02 2.99 0.03 2.88 0.08 
2.45 0.04 2.92 0.05 2.79 0.08 
2.41 O.OI 2.71 0.03 2.69 0.03 
2.35 0.05 2.64 0.05 2.63 0.05 
2.25 0.03 2.60 0.01 2.56 0.02 
2.21 0.05 2.54 O.OI 2.48 0.01 
2.15 0.08 2.47 0.08 2.37 0.01 
2.09 0.02 2.36 O.IO 2.33 0.05 
2.06 0.05 2.29 O.OI 2.24 0.04 
2.23 O.OI 2.17 0.01 
2.19 0.01 2.12 0.01 




POWDER DA TA 
38 39 40 
d,A I / I l d,A I / I , d,A I / I , 
15.50 0.11 7.57 0.75 13.29 0.09 
10.11 0.01 7.11 0.08 12.36 0.04 
8.80 0.15 6.74 0.11 9.51 0.67 
8.15 0.11 6.42 0.88 7.56 0.20 
6.66 0.05 5.72 1.00 6.73 0.17 
6.01 1.00 5.34 0.11 6.53 0.20 
5.70 0.08 5.17 0.47 5.95 0.49 
5.54 0.38 4.88 0.02 5.66 1.00 
5.00 0.28 4.63 0.20 5.40 0.09 
4.87 0.56 4.37 0.47 5.11 0.36 
4.71 0.20 4.17 0.11 4.93 0.07 
4.43 0.08 3.90 0.08 4.78 0.20 
4.12 0.33 3.78 0.20 4.59 0.17 
3.93 0.11 3.65 0.01 4.45 0.07 
3.80 0.11 3.56 0.04 4.32 0.13 
3.68 0.08 3.49 0.04 4.20 0.07 
3.58 0.01 3.38 0.08 4.00 0.24 
3.48 0.04 3.30 0.04 3.89 0.07 
3.28 0.08 3.21 0.15 3.63 0.36 
3.17 0.11 3.03 0.10 3.52 0.13 
3.00 0.20 2.91 0.15 3.41 0.03 
2.92 0.20 2.83 0.05 3.28 0.03 
2.75 0.08 2.67 0.10 3.12 0.09 
2.69 0.05 2.60 0.04 3.00 0.01 
2.63 0.04 2.53 0.02 2.95 0.01 
2.56 0.01 2.49 0.05 2.82 0.17 
2.48 0.04 2.38 0.04 2.67 0.09 
2.34 0.11 2.32 0.04 2.60 0.09 
2.28 0.03 2.24 0.04 2.49 0.04 
2.24 0.08 2.19 0.08 2.42 0.02 
2.19 0.04 2.15 0.11 2.31 0.04 
2.14 0.03 2.09 0.11 2.25 0.04 
2.11 0.04 2.01 0.08 2.21 0.04 
2.04 0.11 2.00 0.04 2.13 0.11 
1.91 0.08 2.07 0.07 
47 
PARSONS, WONG, BEHER AND BAKER 
d,A 
41 42 43 
I / I , d,A I / I , d,A I / I , 
11.05 0.11 14.90 0.04 13.72 0.11 
9.72 0.02 10.87 0.43 11.21 0.15 
8.71 0.41 9.23 0.58 7.60 0.28 
7.17 0.03 7.70 0.04 6.64 0.75 
6.61 0.04 6.31 0.06 5.78 0.15 
6.22 1.00 5.91 0.67 5.47 0.33 
5.97 0.01 5.76 1.00 5.13 1.00 
5.68 0.07 5.58 0.20 4.27 0.94 
5.49 0.08 5.43 0.20 3.89 0.28 
5.11 0.24 5.25 0.36 3.77 0.05 
4.86 0.02 4.91 0.84 3.70 0.05 
4.65 0.02 4.68 0.02 3.58 0.05 
4.34 0.05 4.53 0.36 3.49 0.08 
4.22 0.05 4.42 0.02 3.32 0.05 
3.96 0.11 4.23 0.13 3.27 0.03 
3.76 0.15 4.11 0.20 3.18 0.08 
3.66 0.02 3.73 0.13 2.97 O.IO 
3.57 O.OI 3.60 0.04 2.91 0.10 
3.44 0.02 3.43 0.20 2.67 0.08 
3.33 O.OI 3.23 0.01 2.63 0.05 
3.24 0.04 3.14 0.09 2.54 0.08 
3.18 0.04 3.06 0.09 2.50 0.05 
3.03 O.OI 2.87 0.01 2.37 0.10 
2.90 0.04 2.73 0.02 2.33 0.01 
2.84 0.04 2.69 0.06 2.27 0.05 
2.77 0.01 2.54 0.04 2.22 0.08 
2.58 0.03 2.49 0.09 2.17 0.07 
2.51 0.02 2.39 0.04 2.14 0.03 
2.43 0.03 2.33 0.06 2.10 0.05 
2.31 0.01 2.21 0.09 2.06 0.02 
2.25 0.05 2.16 0.04 2.03 0.02 






POWDER DA TA 
44 45 46 
d.A I / I , d,A I / I , d.A I / I , 
9.21 0.01 8.51 0.50 9.71 0.41 
7.90 0.15 7.28 0.08 9.03 0.02 
6.81 0.20 6.35 0.50 7.83 0.02 
6.53 0.04 6.11 O.OI 6.63 0.01 
6.18 0.11 5.79 0.75 6.03 0.34 
570 1.00 5.20 0.75 5.85 0.02 
5.36 0.20 4.90 0.01 5.56 0.04 
5.01 0.06 4.48 1.00 4.86 0.15 
4.85 0.08 4.27 0.20 4.72 0.01 
4.51 0.13 4.10 0.27 4.10 1.00 
4.12 0.03 3.99 0.27 3.80 0.20 
4.03 0.04 3.82 0.20 3.66 0.02 
3.75 0.03 3.66 0.24 3.54 0.15 
3.63 0.08 3.56 0.10 3.36 0.01 
3.45 0.30 3.45 0.32 3.21 O.OI 
3.28 0.02 3.25 0.27 3.01 0.05 
3.21 0.03 3.05 0.20 2.94 O.OI 
3.08 0.06 2.88 0.10 2.86 0.02 
2.86 0.03 2.83 0.10 2.64 0.01 
2.80 0.04 2.74 0.07 2.45 0.05 
2.71 O.OI 2.66 0.01 2.31 0.02 
2.65 0.08 2.60 0.02 2.24 0.02 
2.53 0.06 2.56 0.07 2.16 0.02 
2.38 0.01 2.46 0.01 2.11 0.02 
2.34 0.03 2.40 0.01 2.06 0.01 
2.30 0.01 2.36 0.01 1.99 0.04 
2.23 0.07 2.27 0.11 
2.17 0.01 2.20 0.02 
2.11 0.03 2.08 0.20 
2.07 0.04 2.04 0.02 
2.02 0.01 1.94 0.01 
1.96 0.04 1.91 0.03 
1.88 0.04 1.88 O.OI 
1.78 0.07 
49 
PARSONS, WONG, BEHER AND BAKER 
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